hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06369090, orgStudyIdInfo id: JP/1/2013, briefTitle: Effect of Breast Size on the Electrical Impedance Tomography Measurement, statusModule overallStatus: COMPLETED, startDateStruct date: 2013-11-01, primaryCompletionDateStruct date: 2014-05-31, completionDateStruct date: 2014-05-31, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Czech Technical University in Prague, class: OTHER, descriptionModule briefSummary: Twenty-two healthy female volunteers were monitored using electrical impedance tomogprahy (EIT) in two different situations. First, with electrode belt placed over the breast tissue and second, with the electrode belt under the breast tissue. The EIT measurement was performed with adjunct spirometric measurement. The changes of regional ventilation related to the breast tissue and the size of breast tissue were evaluated., conditionsModule conditions: Effect of Breast Tissue on EIT Lung Monitoring, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Monitoring of 22 subjects, each subject was measured twice with electrode belt in two different positions., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 22, type: ACTUAL, armsInterventionsModule interventions name: Electrical impedance tomography (EIT), outcomesModule primaryOutcomes measure: Regional ventilation changes possibly caused by the breast tissue, secondaryOutcomes measure: Female subjects enrollment in EIT studies and clinical applications, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Faculty of Biomedical Engineering, Czech Technical University in Prague, city: Kladno, zip: 27201, country: Czechia, geoPoint lat: 50.14734, lon: 14.10285, hasResults: False
protocolSection identificationModule nctId: NCT06369077, orgStudyIdInfo id: CTGlaucoma1, briefTitle: How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-07, completionDateStruct date: 2024-07, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: CT Glaucoma Associates, class: OTHER, descriptionModule briefSummary: IOP effect of half-dose latanoprost dorzolamide-timolol will be compared to full dose. Further comparison will be made timolol-brimonidine-dorzolamide-bimatoprost. Dry eye effects of the different treatments will be assessed., conditionsModule conditions: Glaucoma, Open-Angle, conditions: Glaucoma; Drugs, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: Subjects will have baseline IOP measurements (7-9 am and 3-5 pm) after using using latanoprost every other day and dorzolamide-timolol every morning. They will then randomly be assigned in phase 2 to either: double the frequency to latanoprost daily and dorzolamide-timolol twice daily; or use every morning compounded timolol-brimonidine-dorzolamide-bimatoprost. IOP measurements will be repeated 3 weeks after using the phase 2 medications. For phase 3, subjects will use the treatment to which they were not assigned in phase 2, and IOP measurements will again be repeated 3 weeks later.At each study visit, dry eye signs will be assessed and brief dry eye survey will be administered., primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: Technician measuring IOP and assessing dry eye is masked regarding phase 2 and phase 3 crossover assignment order., whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: dorzolamide/timolol, outcomesModule primaryOutcomes measure: intraocular pressure, secondaryOutcomes measure: dry eye, eligibilityModule sex: ALL, minimumAge: 25 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CT Glaucoma Associates, status: RECRUITING, city: Norwalk, state: Connecticut, zip: 06851, country: United States, contacts name: Peter E Libre, MD, role: CONTACT, phone: 203-853-2020, email: pel3@cumc.columbia.edu, contacts name: Faria Mahjabin, BA, role: CONTACT, email: faria.mahjabin@quinnipiac.edu, geoPoint lat: 41.1176, lon: -73.4079, hasResults: False
protocolSection identificationModule nctId: NCT06369064, orgStudyIdInfo id: 2023A02707-38, briefTitle: Continuous Veno-venous Hemodialysis and Continuous Veno-venous Hemodiafiltration on Urea Reduction Rate in Intensive Care Patient, acronym: CompEER, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-15, primaryCompletionDateStruct date: 2026-08-15, completionDateStruct date: 2026-08-15, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Centre Hospitalier Universitaire de Nīmes, class: OTHER, descriptionModule briefSummary: In patients requiring renal replacement therapy (RRT) in the intensive care unit (ICU), continuous techniques are predominantly using due to better hemodynamic tolerance. The most employed techniques in ICU are continuous venovenous hemodiafiltration (CVVHDF) and continuous venovenous hemodialysis (CVVHD).To our knowledge, there are no prospective studies comparing the efficiency of these two techniques with the same dose of dialysis (and the same filter).In the CompEER study, we aim to compare the efficiency of CVVHD and CVVHDF on urea reduction rate in intensive care patients with acute kidney injury.The research hypothesis is that CVVHD citrate technique is as effective as CVVHDF heparin technique for urea reduction and provides prolonged and stable clearance, facilitating antibiotic management during RRT., conditionsModule conditions: Acute Kidney Injury, conditions: Continuous Renal Replacement Therapy, conditions: Intensive Care Unit, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: CVVHD Dialysis parameters, interventions name: CVVHDF Dialysis parameters, outcomesModule primaryOutcomes measure: urea reduction rate (URR), secondaryOutcomes measure: Creatinine clearance at H24, secondaryOutcomes measure: Urea clearance at H24, secondaryOutcomes measure: Urea clearance at H48, secondaryOutcomes measure: ICU Mortality, secondaryOutcomes measure: Mortality at Day 28, secondaryOutcomes measure: Organ failure-free days at Day 28, secondaryOutcomes measure: Hypokalemia at Day 28, secondaryOutcomes measure: Hypophosphatemia at Day 28, secondaryOutcomes measure: Hypomagnesemia at Day 28, secondaryOutcomes measure: Hyperkalemia at Day 28, secondaryOutcomes measure: Medical Cost, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CHU de Nimes, city: Nîmes, zip: 30029, country: France, contacts name: Claire Roger, MD, PhD, role: CONTACT, email: claire.roger@chu-nimes.fr, contacts name: Claire Roger, MD, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Aurèle Buzancais, MD, role: SUB_INVESTIGATOR, contacts name: Sylvain Garnier, MD, role: SUB_INVESTIGATOR, geoPoint lat: 43.83333, lon: 4.35, hasResults: False
protocolSection identificationModule nctId: NCT06369051, orgStudyIdInfo id: YSEmploy, briefTitle: Supporting Self-employment in Young Adults With Stroke, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Chinese University of Hong Kong, class: OTHER, descriptionModule briefSummary: This project will investigate the effects of an 8-week theory-driven online/hybrid Self-employment Skill Building Intervention on the rate of self-employment, self-efficacy, life satisfaction, and psychosocial outcomes among working-age stroke survivors., conditionsModule conditions: Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 156, type: ESTIMATED, armsInterventionsModule interventions name: Self-employment support intervention, outcomesModule primaryOutcomes measure: Self-employment rate, secondaryOutcomes measure: Self-efficacy, secondaryOutcomes measure: Life satisfaction, secondaryOutcomes measure: Emotional well-being, secondaryOutcomes measure: Community reintegration, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 64 Years, stdAges: ADULT, contactsLocationsModule locations facility: Non-government organisations, status: RECRUITING, city: Hong Kong, country: Hong Kong, contacts name: Suzanne Lo, role: CONTACT, phone: 85239434485, email: suzannelo@cuhk.edu.hk, geoPoint lat: 22.27832, lon: 114.17469, hasResults: False
protocolSection identificationModule nctId: NCT06369038, orgStudyIdInfo id: CUP3222024, briefTitle: Children's Drawing as a Projective Tool to Assess Dental Anxiety, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2025-12-30, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: The aim in this study is to compare the results of anxiety measurement of the child using the CD:H scale with the long-used Face,Legs,Activity,Cry and Consolability scale (FLACC scale) and pulse oximeter reading, to see if the drawing alone can be a reliable tool to predict the child's behaviour before the dental procedure., conditionsModule conditions: Dental Anxiety, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 138, type: ESTIMATED, armsInterventionsModule interventions name: observation of level of dental anxiety in children, outcomesModule primaryOutcomes measure: FLAAC behavioral scale, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06369012, orgStudyIdInfo id: Rania Gamal, briefTitle: Management of Abnormal Uterine Bleeding, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-09-01, completionDateStruct date: 2024-09-30, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Egymedicalpedia, class: INDUSTRY, descriptionModule briefSummary: Abnormal uterine bleeding "AUB" describes all abnormal forms of menstrual bleeding which may result from several causes including anovulation, problems related to pregnancy, infections, vaginal and cervical abnormalities, uterine pathologies including benign and malignant tumors, coagulopathies, endocrine disorders, trauma, foreign bodies, systemic diseases and iatrogenic causes. AUB may be clinically presented by menorrhagia, metrorrhagia or menometrorrhagia. It's the most common complaint for the reproductive age females and accounts for 33% of female patients referred to gynecologists, conditionsModule conditions: Abnormal Uterine Bleeding, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 130, type: ESTIMATED, armsInterventionsModule interventions name: Mefenamic acid 500 mg, outcomesModule primaryOutcomes measure: Bleeding Control, eligibilityModule sex: FEMALE, minimumAge: 15 Years, maximumAge: 45 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Ain Shams University Hospitals, status: RECRUITING, city: Cairo, country: Egypt, contacts name: Rania Gamal Anwar, M.D, role: CONTACT, phone: +201283262383, email: dr.raniagamal2015@yahoo.com, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06368999, orgStudyIdInfo id: EEGCOV, briefTitle: Neurophysiological and Neuropsychological Evalution in Healthcare Workers, acronym: EEGCOV, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-05-27, primaryCompletionDateStruct date: 2020-12-21, completionDateStruct date: 2021-01-09, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to compare in participant population the effect of stress condition on cerebral EEG activity Participants will do an 8 minutes EEG registration. Researchers will compare EEG activity of heathcare workers., conditionsModule conditions: Stress Disorders, Post-Traumatic, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: study of brain EEG activity, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ACTUAL, armsInterventionsModule interventions name: EEG, outcomesModule primaryOutcomes measure: EEG activity, eligibilityModule sex: ALL, minimumAge: 21 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, city: Milan, zip: 20122, country: Italy, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06368986, orgStudyIdInfo id: 222420, briefTitle: A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy Participants, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-16, primaryCompletionDateStruct date: 2024-06-12, completionDateStruct date: 2024-06-12, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: ViiV Healthcare, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to evaluate effect of food (in fasted and fed conditions) on the bioavailability of CAI VH4011499., conditionsModule conditions: HIV Infections, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: VH4011499, outcomesModule primaryOutcomes measure: Area under the plasma concentration - time curve from time zero (pre-dose) to infinity time (AUC[0-inf]) of VH4011499, primaryOutcomes measure: Area under the plasma drug concentration - time curve from zero (pre-dose) to the end of the dosing interval at steady state (AUC[0-tlast) of VH4011499, primaryOutcomes measure: Maximum observed plasma drug concentration (Cmax) of VH4011499, primaryOutcomes measure: Time to maximum observed plasma concentration (Tmax) of VH4011499, secondaryOutcomes measure: Number of participants with AEs (Adverse Events), by severity, secondaryOutcomes measure: Number of participants with maximum toxicity grade increase from baseline for liver laboratory parameters, secondaryOutcomes measure: Change from baseline in liver panel parameters: total bilirubin and direct bilirubin (micromoles per liter), secondaryOutcomes measure: Change from baseline in liver panel parameters: ALT, ALP and AST (International units per liter), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06368973, orgStudyIdInfo id: RC16-4-2023, briefTitle: Mechanical Ventilation-Associated Complications and Co-Morbidities in Children Admitted in Pediatric Intensive Care Unit, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-01-01, primaryCompletionDateStruct date: 2023-12-01, completionDateStruct date: 2023-12-31, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Benha University, class: OTHER, descriptionModule briefSummary: The goal of this study was to identify the prevalence of mechanical ventilation-associated complications and co-morbidities in pediatric patients admitted to the PICU of Benha University Hospital, uncover how often these problems occur, their types, factors linked to them and to compare the epidemiology of MV-associated complications., conditionsModule conditions: Mechanical Ventilation Complication, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 315, type: ACTUAL, outcomesModule primaryOutcomes measure: Adverse events associated with mechanical ventilation, eligibilityModule sex: ALL, minimumAge: 1 Month, maximumAge: 16 Years, stdAges: CHILD, contactsLocationsModule locations facility: Benha University Hospital, city: Cairo, zip: 13511, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06368960, orgStudyIdInfo id: BM201-1001, secondaryIdInfos id: CTR20223162, type: REGISTRY, domain: National Medical Products Administration, briefTitle: BM201 in Combination With Radiotherapy in Patients With Advanced Solid Tumors, acronym: BM201-1001, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-11-07, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: InnoBM Pharmaceuticals Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: This is a non-randomized，open-label，controlled multi-center Phase Ⅰ study to evaluate tolerability, pharmacokinetics, and preliminary efficacy of BM201 injection in combination with radiotherapy in patients with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors who have failed standard therapy or are unable to receive standard treatment., conditionsModule conditions: Advanced Solid Tumors, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: Radiotherapy, interventions name: BM201 injection, outcomesModule primaryOutcomes measure: DLT and MTD, primaryOutcomes measure: Pharmacokinetic (PK) parameters, primaryOutcomes measure: Number of patients with adverse events (AEs), secondaryOutcomes measure: ORR, secondaryOutcomes measure: Peripheral blood cytokine profiling in study participants., secondaryOutcomes measure: The variation in peripheral blood tumor biomarker concentrations., secondaryOutcomes measure: Other exploring outcomes, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Nanjing Drum Towel Hospital /The Affiliated Hospital of Nanjing University Medical School, status: RECRUITING, city: Nanjing, state: Jiangsu, zip: 210008, country: China, contacts name: Juan L GCP Director, role: CONTACT, phone: 800-555-5555, email: njglyygcp@163.com, contacts name: Baorui L Chief Physician, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False
protocolSection identificationModule nctId: NCT06368947, orgStudyIdInfo id: B.30.2.ATA.0.01.00/172, briefTitle: Therapeutic Play on Pain Tolerance and Emotion Regulation in Children, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-29, primaryCompletionDateStruct date: 2024-12-29, completionDateStruct date: 2026-12-29, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Ataturk University, class: OTHER, descriptionModule briefSummary: The research is a randomized controlled experimental study. The population of the research will consist of 10-18 year old children who were diagnosed with acute lymphoblastic leukemia and received chemotherapy, who were admitted to the Children's Hematology Clinic of Adana City Training and Research Hospital between 19.05.2024 and 19.05.2025. Therapeutic play sessions will occur over a 4-week period during chemotherapy treatment., conditionsModule conditions: Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 66, type: ESTIMATED, armsInterventionsModule interventions name: Therapeutic Play, outcomesModule primaryOutcomes measure: Pain Tolerance Scale for Children with Cancer, primaryOutcomes measure: Emotion Regulation Scale for Children and Adolescents, eligibilityModule sex: ALL, minimumAge: 10 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Ataturk University Nursing of Faculty, status: RECRUITING, city: Erzurum, zip: 25240, country: Turkey, contacts name: ARZU SARIALİOĞLU, PHD, role: CONTACT, phone: 04422315795, email: arzu.celebi@atauni.edu.tr, geoPoint lat: 39.90861, lon: 41.27694, hasResults: False
protocolSection identificationModule nctId: NCT06368921, orgStudyIdInfo id: VRT106-C01, briefTitle: A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-09, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Guangzhou Virotech Pharmaceutical Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: To Evaluate the safety and tolerability of single and multiple intratumoral injections of recombinant oncolytic virus M1 (VRT106) in patients with locally advanced/metastatic solid tumors., conditionsModule conditions: Solid Tumor, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: VRT106, outcomesModule primaryOutcomes measure: Evaluate the safety and tolerability of escalating doses of intratumoral injection of VRT106., primaryOutcomes measure: Characterize the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) levels., secondaryOutcomes measure: Examine the biological distribution characteristics and shedding patterns of intratumoral injection of VRT106., secondaryOutcomes measure: Assess the immunogenicity of intratumoral injection of VRT106., secondaryOutcomes measure: Assess the anti-tumor effect of VRT106, including objective response rate (ORR) as efficacy indicators., secondaryOutcomes measure: Assess the anti-tumor effect of VRT106, including disease control rate (DCR) as efficacy indicators., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sun Yat-sen University Cancer Center, status: RECRUITING, city: Guangzhou, state: Guangdong, country: China, contacts name: Hongyun Zhao, role: CONTACT, email: zhaohy@syscc.org.cn, geoPoint lat: 23.11667, lon: 113.25, hasResults: False